SCHEMBL1765877

SCHEMBL1765877

C[C](C)c1ncc[nH]1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7695257 0.82
SCHEMBL317174 0.80
SCHEMBL6159271 0.80
SCHEMBL98748 0.80
SCHEMBL20742881 0.80
SCHEMBL4083095 0.78
SCHEMBL22710195 0.78 NPC1 (0.43)
Hydrochloric Acid SCHEMBL7212556 0.78
SCHEMBL28825040 0.78
Ammonia Solution, Strong SCHEMBL27514119 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107661758-B Preparation method and application of 2-methylimidazolyl hierarchical pore catalyst carbon material 江苏大学 2020-06-09 CN disclosed
WO-2015051268-A2 HIV PROTEASE INHIBITORS AGAINST PICORNAVIRUS INFECTION THE JOHNS HOPKINS UNIVERSITY (US) 2015-04-09 WO disclosed
EP-2464349-A2 USE OF PPAR DELTA LIGANDS FOR THE TREATMENT OR PREVENTION OF INFLAMMATION OR ENERGY METABOLISM/PRODUCTION RELATED DISEASES Cerenis Therapeutics S.A. (FR) 2012-06-20 EP disclosed
WO-2011020001-A9 USE OF PPAR DELTA LIGANDS FOR THE TREATMENT OR PREVENTION OF INFLAMMATION OR ENERGY METABOLISM/PRODUCTION RELATED DISEASES CERENIS THERAPEUTICS S.A. (FR) 2011-05-26 WO disclosed
WO-2011020001-A2 USE OF PPAR DELTA LIGANDS FOR THE TREATMENT OR PREVENTION OF INFLAMMATION OR ENERGY METABOLISM/PRODUCTION RELATED DISEASES CERENIS THERAPEUTICS S.A. (FR) 2011-02-17 WO disclosed
US-7521551-B2 Chlorins possessing fused ring systems useful as photoselective compounds for photodynamic therapy MIRAVANT PHARMACEUTICALS, INC. (US) 2009-04-21 US disclosed
US-20080275232-A1 CHLORINS POSSESSING FUSED RING SYSTEMS USEFUL AS PHOTOSELECTIVE COMPOUNDS FOR PHOTODYNAMIC THERAPY MIRAVANT PHARMACEUTICALS, INC. 2008-11-06 US disclosed
EP-0931071-B1 METHODS OF MAKING HIV-PROTEASE INHIBITORS AND INTERMEDIATES FOR MAKING THEM AGOURON PHARMA (US) 2008-06-04 EP disclosed
EP-1340744-B1 Hiv protease inhibitors AGOURON PHARMA (US) 2007-05-23 EP disclosed
US-7173059-B2 Intermediates useful in the synthesis of HIV-protease inhibitors and methods for preparing the same AGOURON PHARMACEUTICALS, INC. (US) 2007-02-06 US disclosed
US-5480887-A FOR HIV, THIENO(3,2-C)PYRIDINE-(6S)-CARBOXAMIDES ELI LILLY AND COMPANY (US) 1996-01-02 US disclosed
WO-1995032185-A1 N-(3-AMINO-2-HYDROXYBUTYL)SULPHONAMIDE DERIVATIVES AS HIV PROTEASE INHIBITORS AGOURON PHARMACEUTICALS, INC. (US) 1995-11-30 WO disclosed
WO-1995020962-A1 PROTEASE INHIBITORS ELI LILLY AND COMPANY (US) 1995-08-10 WO disclosed
WO-1995009843-A1 HIV PROTEASE INHIBITORS AGOURON PHARMACEUTICALS, INC. (US) 1995-04-13 WO disclosed
EP-0609625-A1 Inhibitors of HIV protease useful for the treatment of AIDS ELI LILLY AND COMPANY (US) 1994-08-10 EP disclosed
EP-0604184-A1 Inhibitors of HIV protease useful for the treatment of aids ELI LILLY AND COMPANY (US) 1994-06-29 EP disclosed
EP-0604185-A1 Inhibitors of HIV protease useful for the treatment of aids ELI LILLY AND COMPANY (US) 1994-06-29 EP disclosed
EP-0604186-A1 Inhibitors of HIV protease useful for the treatment of aids ELI LILLY AND COMPANY (US) 1994-06-29 EP disclosed
EP-0604182-A2 Inhibitors of HIV protease useful for the treatment of Aids ELI LILLY AND COMPANY (US) 1994-06-29 EP disclosed
EP-0575097-A1 2,3-Bis-carboxamidomethyl substituted oxiranes as inhibitors of HIV protease and their use for the treatment of AIDS ELI LILLY AND COMPANY (US) 1993-12-22 EP disclosed